Accession Number: | 0001209191-23-009207 |
Date: | 2023-02-10 |
Issuer: | KINNATE BIOPHARMA INC. (KNTE) |
Original Submission Date: |
KRISHNAMOHAN NEHA
103 MONTGOMERY STREET, SUITE 150
THE PRESIDIO OF SAN FRANCISCO
SAN FRANCISCO, CA 94129
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
EMPLOYEE STOCK OPTION (RIGHT TO BUY) | 6.78 | 2023-02-10 | deemed execution date | A | 215,000 (a) | 2033-02-10 | common stock 215,000 | $6.78 | 215,000 | direct |
ID | footnote |
---|---|
f1 | one forty-eighth (1/48th) of the total number of shares granted under the option shall vest and become exercisable starting on march 1, 2023 (the "vesting commencement date") and thereafter each month on the same day of the month as the vesting commencement date, until all shares subject to the option have vested on february 1, 2027, subject to the reporting person continuing to be a service provider through each such date. |